Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

dministered, small molecule pharmacological chaperone being developed for the treatment of Pompe disease. In June 2008 Amicus initiated Phase 2 clinical trials of HGT-3510, an orally administered, small molecule pharmacological chaperone being jointly developed for the treatment of Pompe disease by Shire and Amicus. This trial was placed on clinical hold in February 2009 in response to reports of two serious adverse events probably related to treatment with HGT-3510. Shire has rights to HGT-3510 in markets outside the US.

Early Research Products

A number of additional projects are underway in the early stages of development for the HGT business area.

Business Development

As a result of the issues associated with the loss or expiry of patent protection or market exclusivity, Shire seeks to focus its business development activity on the acquisition and in-licensing of products and projects which have the benefit of long-term patent protection and market exclusivity.

The Group remains active in seeking out opportunities to acquire new products or companies that fit its business strategy, its existing therapeutic areas or are in complementary therapeutic areas. During 2008 Shire:

    - acquired more than 98% of Jerini, adding Jerini's HAE product, FIRAZYR,
      to the portfolio; and

    - acquired the global rights to METAZYM, a clinical candidate
      arylsulfatase-A, from Zymenex.

In 2007, the Group acquired New River, allowing Shire to capture the full economic value of VYVANSE and gain control of the development and commercialization of this product. In 2007 Shire also in-licensed the rights to AMIGAL, PLICERA and AT-2220, three pharmacological chaperone compounds for lysosomal storage disorders in markets outside the US; SPD550 for Celiac disease in markets outside of the US and Japan; and worldwide rights (excluding EU member states) to
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , Mar. 05, 2015 Research and Markets ... the "Mature Biotech Outlook 2015: New Therapy Ventures ... offering. All biotech companies - Gilead ... in past year, have given a positive return and ... have been able to select therapy/niche indication where the ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 The next ... have received the CE mark (European) approval. The CE ... Free Trade Association (EFTA) and the European Union. Following ... now been granted to implants supplied by the Turkey-based ... conditions. , Osimplant's Cervical Expandable Bladed HA PEEK ...
(Date:3/4/2015)... -- In an article published and posted online today, ... review the clinical aspects of diseases caused by 5 ... article, "Clinical Management of Potential Bioterrorism-Related Conditions," was published ... New England Journal of Medicine . ... Tom Inglesby—review the clinical management of conditions resulting from ...
(Date:3/4/2015)... March 04, 2015 USDM Life ... the life sciences industry, hired David Blewitt ... Cloud Compliance Services and Solutions at USDM Life ... based applications while maintaining compliance with government regulations worldwide. ... been an accomplished life sciences regulatory and IS compliance ...
Breaking Biology Technology:Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3Latest Clinical Information On Bioterrorism Threats 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3
... crowd who is proud to announce their compulsive habit of ... job classifieds. , ,Don't get me wrong. I don't spend ... communication skills" and the ever popular "outstanding communication skills." I ... it happens to be my first day on a new ...
... Milwaukee Rockwell Automation Inc. has increased ... 22.5 cents per share, up from 16.5 cents, ... Nosbusch said the change reflected strong earnings and ... ,Rockwell makes control and automation systems for industrial ...
... building relationships that will carry into your personal and professional ... on networking just for your employer. , ,The relationships you ... with you from job to job. Treat every relationship you ... will find it valuable to have some of these people ...
Cached Biology Technology:Is IT leadership a position or an attitude? 2Is IT leadership a position or an attitude? 3Networking for your employer is great for building your personal Rolodex 2Networking for your employer is great for building your personal Rolodex 3
(Date:3/2/2015)... , March 2, 2015   Neurotechnology , ... today introduced the SentiGaze Software Development Kit ... create applications that use off-the-shelf webcams to track eye ... gazes at a monitor. Heatmaps can be used for ... effectiveness of online advertising. The SDK can also be ...
(Date:2/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/sxwl43/global_2d_gesture ) ... 2D Gesture Recognition Market 2015-2019" report to ... the Global 2D Gesture Recognition market to grow ... 2014-2019 The increased demand for gesture-enabled ... the major trends in the market. The growing ...
(Date:2/13/2015)... Feb. 13, 2015 ACT Genomics Co., ... aims to transform cancer genomic information into precision ... company has raised US$ 8 million in the its ... Taipei, Taiwan , ACT Genomics ... With the aim to implement next generation sequencing ...
Breaking Biology News(10 mins):Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2
... include understanding new evidence for rock pulverization by catastrophic ... examples of active arc-continent collision in Taiwan; discovery and ... Earth, located in Japan; the puzzling record of the ... last 500 million years; and a possible refutation of ...
... the tropical fish known as swordtail characins have flag-like sex ... fishing rod would. What,s more, a study reported online on ... publication, shows just what any good fly-fisherman would know: Lures ... often eat. For some characins in the study, that means ...
... . , It is not unusual for babies to ... of the heart in the embryo is a process which is ... Planck Institute for Heart and Lung Research in Bad Nauheim have ... regulating the function of stem cells in the heart. As a ...
Cached Biology News:Pulverized rocks, coral reefs, seawater chemistry, and continental collisions 2Pulverized rocks, coral reefs, seawater chemistry, and continental collisions 3Pulverized rocks, coral reefs, seawater chemistry, and continental collisions 4Male sex ornaments are fishing lures, literally 2Finished heart switches stem cells off 2Finished heart switches stem cells off 3
...
... PCR specificity *High PCR specificity ... with unique QIAGEN PCR Buffer ... by the stringent built-in hot start ... Mix and simple reaction setup at ...
... Nuclear matrix proteins (NMPs) make up the internal ... with such functions as DNA replication, RNA synthesis, ... has been shown to be highly insoluble ... cell death releases soluble nuclear matrix proteins that ...
Request Info...
Biology Products: